ONCOSIL MEDICAL LTD - Announcements

Market Cap $45.40M Add to my watchlist

Technology Scientific & Technical Instruments

OncoSil Medical Ltd is an Australia-based medical device company focused on localized... OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.More

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutioniSe neurodevelopmental condition diagnosis like ASD and ADHD. Born from extensive research at Princeton University,...

Announcements

Filter Results

All Price Sensitive Only

OSL	Notice of Extraordinary General Meeting/Proxy Form		20/08/24	405.44KB	Share
OSL	Significant Growth in Commercial Treatment Sales in Q4 FY24		15/08/24	148.53KB	Share
OSL	Successful Treatment with OncoSil Device in Turkiye	PRICE SENSITIVE	15/08/24	149.09KB	Share
OSL	Ceasing to be a substantial holder SC		14/08/24	122.41KB	Share
OSL	Prospectus	PRICE SENSITIVE	07/08/24	346.4KB	Share
OSL	Application for quotation of securities - OSL		07/08/24	15.73KB	Share
OSL	Notice of Initial Substantial Holding from SOL		31/07/24	381.88KB	Share
OSL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	695.26KB	Share
OSL	Becoming a substantial holder from PCG		30/07/24	364.21KB	Share
OSL	Notice under section 708A		29/07/24	147.32KB	Share
OSL	Application for quotation of securities - OSL		29/07/24	15.81KB	Share
OSL	Proposed issue of securities - OSL		25/07/24	14.93KB	Share
OSL	Proposed issue of securities - OSL		25/07/24	16.92KB	Share
OSL	Australian institution to invest $2.7 million in OSL	PRICE SENSITIVE	25/07/24	157.96KB	Share
OSL	Investor Presentation		23/07/24	3MB	Share
OSL	Peter Hall to be appointed Non-Executive Director (addendum)		15/07/24	123.38KB	Share
OSL	Director Appointment/Resignation PH		15/07/24	120.96KB	Share
OSL	Letter to Short Dated Option Holders		12/07/24	77.07KB	Share
OSL	OSL Short Dated Options Range of Units and Top 20 Holders		10/07/24	172.98KB	Share
OSL	Application for quotation of securities - OSL		10/07/24	18.9KB	Share
OSL	Notification regarding unquoted securities - OSL		03/07/24	14.6KB	Share
OSL	Application for quotation of securities - OSL		03/07/24	17.09KB	Share
OSL	Notification regarding unquoted securities - OSL		24/06/24	14.45KB	Share
OSL	Proposed issue of securities - OSL		21/06/24	14.54KB	Share
OSL	5th patient is treated in PANCOSIL trial		11/06/24	131.92KB	Share
OSL	200th patient treated with the OncoSil device		03/06/24	175.38KB	Share
OSL	OncoSil signs distribution agreement for Saudi Arabia		23/05/24	181.8KB	Share
OSL	Change in substantial holding		20/05/24	98.34KB	Share
OSL	Notification regarding unquoted securities - OSL		20/05/24	14.47KB	Share
OSL	Application for quotation of securities - OSL		20/05/24	18.1KB	Share
OSL	Notification regarding unquoted securities - OSL		15/05/24	14.83KB	Share
OSL	Application for quotation of securities - OSL		15/05/24	17.16KB	Share
OSL	Results of Meeting		15/05/24	174.09KB	Share
OSL	Notification regarding unquoted securities - OSL		10/05/24	14.83KB	Share
OSL	Application for quotation of securities - OSL		10/05/24	17.15KB	Share
OSL	Notification regarding unquoted securities - OSL		08/05/24	14.83KB	Share
OSL	Application for quotation of securities - OSL		08/05/24	17.15KB	Share
OSL	Notification regarding unquoted securities - OSL		03/05/24	14.79KB	Share
OSL	Application for quotation of securities - OSL		03/05/24	17.11KB	Share
OSL	Notification regarding unquoted securities - OSL		02/05/24	14.76KB	Share
OSL	Application for quotation of securities - OSL		02/05/24	17.05KB	Share
OSL	$5.3 million raised under Entitlement Offer	PRICE SENSITIVE	02/05/24	164.95KB	Share
OSL	1st Study in Man Increases Pancreatic Tumor Vascularity	PRICE SENSITIVE	01/05/24	183.01KB	Share
OSL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	385.2KB	Share
OSL	Two more PANCOSIL Trial treatments using OncoSil device		17/04/24	158.85KB	Share
OSL	First patient treated with OncoSil device in Turkiye	PRICE SENSITIVE	16/04/24	200.86KB	Share
OSL	Notice of Extraordinary General Meeting/Proxy Form		16/04/24	435.73KB	Share
OSL	First patient treated in the UK for the TRIPP-FXX study	PRICE SENSITIVE	12/04/24	250.74KB	Share
OSL	UK Private Insurer Approves Reimbursement for OncoSil		09/04/24	187.45KB	Share
OSL	First Austria-based treatments utilising the OncoSil device	PRICE SENSITIVE	05/04/24	360.47KB	Share
OSL	Dispatch of Entitlement Offer Prospectus		04/04/24	242.33KB	Share
OSL	Notice under section 708A		28/03/24	146.57KB	Share
OSL	Application for quotation of securities - OSL		28/03/24	15.62KB	Share
OSL	Prospectus - Entitlement Offer	PRICE SENSITIVE	25/03/24	687.2KB	Share
OSL	Update - Proposed issue of securities - OSL		22/03/24	26.63KB	Share
OSL	Placement and Entitlement Offer - amended timetable		22/03/24	130.23KB	Share
OSL	Update - Proposed issue of securities - OSL		22/03/24	27.1KB	Share
OSL	Placement and Entitlement Offer - addendum		21/03/24	181KB	Share
OSL	Investor Presentation		20/03/24	2.45MB	Share
OSL	Proposed issue of securities - OSL		20/03/24	27.77KB	Share
OSL	Proposed issue of securities - OSL		20/03/24	19.69KB	Share
OSL	Proposed issue of securities - OSL		20/03/24	15.42KB	Share
OSL	Placement and Entitlement Offer to raise up to $7.1 million	PRICE SENSITIVE	20/03/24	211.12KB	Share
OSL	Trading Halt	PRICE SENSITIVE	18/03/24	188.77KB	Share
OSL	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	28/02/24	642.15KB	Share
OSL	OncoSil signs distribution agreement for Turkish market		01/02/24	223.63KB	Share
OSL	84 German hospitals can negotiate fee for Oncosil device	PRICE SENSITIVE	01/02/24	185.79KB	Share
OSL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	489.98KB	Share
OSL	Change of Director's Interest Notice DC NL GL		20/12/23	327.86KB	Share
OSL	Notification regarding unquoted securities - OSL		19/12/23	27.65KB	Share
OSL	Notification regarding unquoted securities - OSL		19/12/23	25.39KB	Share
OSL	Proposed issue of securities - OSL		18/12/23	26.5KB	Share
OSL	Notification of cessation of securities - OSL		18/12/23	21.62KB	Share
OSL	OncoSil receives $1.1m R&D tax incentive	PRICE SENSITIVE	15/12/23	162.74KB	Share
OSL	First two commercial patient treatments in Greece	PRICE SENSITIVE	08/12/23	266.8KB	Share
OSL	Notification of cessation of securities - OSL		06/12/23	21.65KB	Share
OSL	Final Director's Interest Notice BL		05/12/23	209.43KB	Share
OSL	Results of Annual General Meeting		29/11/23	172.01KB	Share
OSL	Presentation to Annual General Meeting		29/11/23	3.3MB	Share
OSL	OncoSil onboards first patient in PANCOSIL Clinical Trial	PRICE SENSITIVE	29/11/23	230.11KB	Share
OSL	OncoSil gaining traction in the Israeli healthcare market		24/11/23	201.06KB	Share
OSL	Notice of Annual General Meeting/Proxy Form		31/10/23	732.26KB	Share
OSL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/23	353.28KB	Share
OSL	Date of AGM and Closing Date for Director Nominations		04/10/23	167.86KB	Share
OSL	Mr Brian Leedman to retire from the Board of OncoSil		18/09/23	170.4KB	Share
OSL	Notification of cessation of securities - OSL		13/09/23	21.62KB	Share
OSL	Final Director's Interest Notice OB		31/08/23	184.41KB	Share
OSL	Otto Buttula retires and Douglas Cubbin appointed Chair		31/08/23	252.71KB	Share
OSL	Appendix 4G		31/08/23	263.76KB	Share
OSL	Corporate Governance Statement		31/08/23	163.84KB	Share
OSL	Appendix 4E and Annual Report	PRICE SENSITIVE	31/08/23	2.22MB	Share
OSL	Change of principal place of business		16/08/23	170.64KB	Share
OSL	Initial Director's Interest Notice		10/08/23	201.51KB	Share
OSL	Douglas Cubbin appointed as Incoming Chairman of OncoSil		07/08/23	261.42KB	Share
OSL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	356.23KB	Share
OSL	Initial Director's Interest Notice GL		18/07/23	202.27KB	Share
OSL	Gabriel Liberatore appointed to the Board of OncoSil		14/07/23	171.34KB	Share
OSL	Change of Directors Interest Notice - Appendix 3Y OB		04/07/23	229.99KB	Share
OSL	Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer	PRICE SENSITIVE	30/06/23	226.69KB	Share
OSL	Notification of cessation of securities - OSL		29/06/23	23.85KB	Share

OSL Notice of Extraordinary General Meeting/Proxy Form
20/08/24		405.44KB	Share
OSL Significant Growth in Commercial Treatment Sales in Q4 FY24
15/08/24		148.53KB	Share
OSL Successful Treatment with OncoSil Device in Turkiye
15/08/24	PRICE SENSITIVE	149.09KB	Share
OSL Ceasing to be a substantial holder SC
14/08/24		122.41KB	Share
OSL Prospectus
07/08/24	PRICE SENSITIVE	346.4KB	Share
OSL Application for quotation of securities - OSL
07/08/24		15.73KB	Share
OSL Notice of Initial Substantial Holding from SOL
31/07/24		381.88KB	Share
OSL Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	695.26KB	Share
OSL Becoming a substantial holder from PCG
30/07/24		364.21KB	Share
OSL Notice under section 708A
29/07/24		147.32KB	Share
OSL Application for quotation of securities - OSL
29/07/24		15.81KB	Share
OSL Proposed issue of securities - OSL
25/07/24		14.93KB	Share
OSL Proposed issue of securities - OSL
25/07/24		16.92KB	Share
OSL Australian institution to invest $2.7 million in OSL
25/07/24	PRICE SENSITIVE	157.96KB	Share
OSL Investor Presentation
23/07/24		3MB	Share
OSL Peter Hall to be appointed Non-Executive Director (addendum)
15/07/24		123.38KB	Share
OSL Director Appointment/Resignation PH
15/07/24		120.96KB	Share
OSL Letter to Short Dated Option Holders
12/07/24		77.07KB	Share
OSL OSL Short Dated Options Range of Units and Top 20 Holders
10/07/24		172.98KB	Share
OSL Application for quotation of securities - OSL
10/07/24		18.9KB	Share
OSL Notification regarding unquoted securities - OSL
03/07/24		14.6KB	Share
OSL Application for quotation of securities - OSL
03/07/24		17.09KB	Share
OSL Notification regarding unquoted securities - OSL
24/06/24		14.45KB	Share
OSL Proposed issue of securities - OSL
21/06/24		14.54KB	Share
OSL 5th patient is treated in PANCOSIL trial
11/06/24		131.92KB	Share
OSL 200th patient treated with the OncoSil device
03/06/24		175.38KB	Share
OSL OncoSil signs distribution agreement for Saudi Arabia
23/05/24		181.8KB	Share
OSL Change in substantial holding
20/05/24		98.34KB	Share
OSL Notification regarding unquoted securities - OSL
20/05/24		14.47KB	Share
OSL Application for quotation of securities - OSL
20/05/24		18.1KB	Share
OSL Notification regarding unquoted securities - OSL
15/05/24		14.83KB	Share
OSL Application for quotation of securities - OSL
15/05/24		17.16KB	Share
OSL Results of Meeting
15/05/24		174.09KB	Share
OSL Notification regarding unquoted securities - OSL
10/05/24		14.83KB	Share
OSL Application for quotation of securities - OSL
10/05/24		17.15KB	Share
OSL Notification regarding unquoted securities - OSL
08/05/24		14.83KB	Share
OSL Application for quotation of securities - OSL
08/05/24		17.15KB	Share
OSL Notification regarding unquoted securities - OSL
03/05/24		14.79KB	Share
OSL Application for quotation of securities - OSL
03/05/24		17.11KB	Share
OSL Notification regarding unquoted securities - OSL
02/05/24		14.76KB	Share
OSL Application for quotation of securities - OSL
02/05/24		17.05KB	Share
OSL $5.3 million raised under Entitlement Offer
02/05/24	PRICE SENSITIVE	164.95KB	Share
OSL 1st Study in Man Increases Pancreatic Tumor Vascularity
01/05/24	PRICE SENSITIVE	183.01KB	Share
OSL Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	385.2KB	Share
OSL Two more PANCOSIL Trial treatments using OncoSil device
17/04/24		158.85KB	Share
OSL First patient treated with OncoSil device in Turkiye
16/04/24	PRICE SENSITIVE	200.86KB	Share
OSL Notice of Extraordinary General Meeting/Proxy Form
16/04/24		435.73KB	Share
OSL First patient treated in the UK for the TRIPP-FXX study
12/04/24	PRICE SENSITIVE	250.74KB	Share
OSL UK Private Insurer Approves Reimbursement for OncoSil
09/04/24		187.45KB	Share
OSL First Austria-based treatments utilising the OncoSil device
05/04/24	PRICE SENSITIVE	360.47KB	Share
OSL Dispatch of Entitlement Offer Prospectus
04/04/24		242.33KB	Share
OSL Notice under section 708A
28/03/24		146.57KB	Share
OSL Application for quotation of securities - OSL
28/03/24		15.62KB	Share
OSL Prospectus - Entitlement Offer
25/03/24	PRICE SENSITIVE	687.2KB	Share
OSL Update - Proposed issue of securities - OSL
22/03/24		26.63KB	Share
OSL Placement and Entitlement Offer - amended timetable
22/03/24		130.23KB	Share
OSL Update - Proposed issue of securities - OSL
22/03/24		27.1KB	Share
OSL Placement and Entitlement Offer - addendum
21/03/24		181KB	Share
OSL Investor Presentation
20/03/24		2.45MB	Share
OSL Proposed issue of securities - OSL
20/03/24		27.77KB	Share
OSL Proposed issue of securities - OSL
20/03/24		19.69KB	Share
OSL Proposed issue of securities - OSL
20/03/24		15.42KB	Share
OSL Placement and Entitlement Offer to raise up to $7.1 million
20/03/24	PRICE SENSITIVE	211.12KB	Share
OSL Trading Halt
18/03/24	PRICE SENSITIVE	188.77KB	Share
OSL Appendix 4D and Half Year Accounts
28/02/24	PRICE SENSITIVE	642.15KB	Share
OSL OncoSil signs distribution agreement for Turkish market
01/02/24		223.63KB	Share
OSL 84 German hospitals can negotiate fee for Oncosil device
01/02/24	PRICE SENSITIVE	185.79KB	Share
OSL Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	489.98KB	Share
OSL Change of Director's Interest Notice DC NL GL
20/12/23		327.86KB	Share
OSL Notification regarding unquoted securities - OSL
19/12/23		27.65KB	Share
OSL Notification regarding unquoted securities - OSL
19/12/23		25.39KB	Share
OSL Proposed issue of securities - OSL
18/12/23		26.5KB	Share
OSL Notification of cessation of securities - OSL
18/12/23		21.62KB	Share
OSL OncoSil receives $1.1m R&D tax incentive
15/12/23	PRICE SENSITIVE	162.74KB	Share
OSL First two commercial patient treatments in Greece
08/12/23	PRICE SENSITIVE	266.8KB	Share
OSL Notification of cessation of securities - OSL
06/12/23		21.65KB	Share
OSL Final Director's Interest Notice BL
05/12/23		209.43KB	Share
OSL Results of Annual General Meeting
29/11/23		172.01KB	Share
OSL Presentation to Annual General Meeting
29/11/23		3.3MB	Share
OSL OncoSil onboards first patient in PANCOSIL Clinical Trial
29/11/23	PRICE SENSITIVE	230.11KB	Share
OSL OncoSil gaining traction in the Israeli healthcare market
24/11/23		201.06KB	Share
OSL Notice of Annual General Meeting/Proxy Form
31/10/23		732.26KB	Share
OSL Quarterly Activities/Appendix 4C Cash Flow Report
30/10/23	PRICE SENSITIVE	353.28KB	Share
OSL Date of AGM and Closing Date for Director Nominations
04/10/23		167.86KB	Share
OSL Mr Brian Leedman to retire from the Board of OncoSil
18/09/23		170.4KB	Share
OSL Notification of cessation of securities - OSL
13/09/23		21.62KB	Share
OSL Final Director's Interest Notice OB
31/08/23		184.41KB	Share
OSL Otto Buttula retires and Douglas Cubbin appointed Chair
31/08/23		252.71KB	Share
OSL Appendix 4G
31/08/23		263.76KB	Share
OSL Corporate Governance Statement
31/08/23		163.84KB	Share
OSL Appendix 4E and Annual Report
31/08/23	PRICE SENSITIVE	2.22MB	Share
OSL Change of principal place of business
16/08/23		170.64KB	Share
OSL Initial Director's Interest Notice
10/08/23		201.51KB	Share
OSL Douglas Cubbin appointed as Incoming Chairman of OncoSil
07/08/23		261.42KB	Share
OSL Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	356.23KB	Share
OSL Initial Director's Interest Notice GL
18/07/23		202.27KB	Share
OSL Gabriel Liberatore appointed to the Board of OncoSil
14/07/23		171.34KB	Share
OSL Change of Directors Interest Notice - Appendix 3Y OB
04/07/23		229.99KB	Share
OSL Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer
30/06/23	PRICE SENSITIVE	226.69KB	Share
OSL Notification of cessation of securities - OSL
29/06/23		23.85KB	Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last 1.2¢		Change 0.001(9.09%)		Mkt cap ! $45.40M

Open	High	Low	Value	Volume
1.1¢	1.2¢	1.1¢	$18.92K	1.705M

Buyers (Bids)

No.	Vol.	Price($)
25	13619110	1.0¢

Sellers (Offers)

Price($)	Vol.	No.
1.2¢	5063491	9

View Market Depth

No.	Vol.	Price($)
24	13469110	0.010
23	14339583	0.009
10	6887500	0.008
13	6339285	0.007
8	8595000	0.006

Price($)	Vol.	No.
0.012	4158618	8
0.013	11108832	8
0.014	6187166	8
0.015	8500000	3
0.016	4766668	3

Last trade - 16.10pm 23/08/2024 (20 minute delay)


Last 1.1¢		Change 0.001 ( 0.00 %)
Open	High	Low	Volume
1.1¢	1.1¢	1.1¢	1930379
Last updated 14.48pm 23/08/2024 ?

OSL (ASX) Chart

ONCOSIL MEDICAL LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories